Sorafenib in metastatic MTC 每 a case report and minireview of the literature

作者：Mila Petrova; Zhasmina Mihaylova; Albena Fakirova

来源：International Medical Case Reports Journal, 2010.

DOI：http://dx.doi.org/10.2147/IMCRJ.S9384

• medullary thyroid cancer
• tumor response
• cardiotoxicity
• TKIs

rafenib in metastatic MTC 每 a case report and minireview of the literature Case report (3852) Total Article Views Authors: Mila Petrova, Zhasmina Mihaylova, Albena Fakirova Published Date May 2010 Volume 2010:3 Pages 55 - 58 DOI: http://dx.doi.org/10.2147/IMCRJ.S9384 Mila Petrova1, Zhasmina Mihaylova1, Albena Fakirova2 1Hematology and Oncology Department, 2Pathology Department, Medical Military Academy, Sofia, Bulgaria Abstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients＊ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.